Using bioinformatics analysis, the present study showed that dasatinib might have therapeutic potential in HCC, and YES1 expression was positively associated with immune infiltration, suggesting that YES1 inhibitor combined with immunotherapy might have a synergistic function in patients with HCC. Here, YES1 is linked to hepatocellular carcinoma.